JANSSEN PHARMACEUTICAL K.K.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: ALS-008176 (750 mg)
Drug: ALS-008176 (250 mg)
Drug: ALS-008176 (500 mg)
Other: Placebo

First Posted Date: 2015-06-23

Last Posted Date: 2016-07-11

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 24

Registration Number: NCT02478333

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Phase 4

Completed

Conditions: Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Prednisolone

First Posted Date: 2015-04-01

Last Posted Date: 2018-12-21

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 51

Registration Number: NCT02405858

An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Phase 2

Completed

Conditions: Tuberculosis, Multidrug-Resistant

Interventions: Drug: TMC207 (bedaquiline)
Drug: Background Regimen (BR)

First Posted Date: 2015-02-19

Last Posted Date: 2019-11-01

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 6

Registration Number: NCT02365623

Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: JNJ-54861911, 10 mg
Drug: JNJ-54861911, 50 mg
Drug: Placebo

First Posted Date: 2015-02-10

Last Posted Date: 2019-02-04

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 18

Registration Number: NCT02360657

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Phase 3

Completed

Conditions: Pustular Psoriasis

Interventions: Drug: Guselkumab

First Posted Date: 2015-01-22

Last Posted Date: 2019-10-24

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 21

Registration Number: NCT02343744

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: CNTO 1959 50 mg
Drug: CTNO 1959 100 mg
Drug: Placebo 50 mg
Drug: Placebo 100 mg

First Posted Date: 2014-12-24

Last Posted Date: 2020-05-22

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 192

Registration Number: NCT02325219

Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: CNTO 3649 100 mcg/kg
Drug: CNTO 3649 300 mcg/kg
Drug: Placebo
Drug: CNTO 3649 10 mcg/kg
Drug: CNT0 3649 30 mcg/kg

First Posted Date: 2014-08-25

Last Posted Date: 2014-09-09

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 64

Registration Number: NCT02224118

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-54861911 (25 mg)
Drug: JNJ-54861911 (100 mg)
Drug: JNJ-54861911 (50 mg)
Drug: Placebo

First Posted Date: 2014-07-02

Last Posted Date: 2014-09-12

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 24

Registration Number: NCT02180269

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Mantle-cell

Interventions: Drug: Ibrutinib

First Posted Date: 2014-06-23

Last Posted Date: 2017-01-24

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 16

Registration Number: NCT02169180

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Drug: JNJ-56021927

First Posted Date: 2014-06-13

Last Posted Date: 2020-04-27

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 6

Registration Number: NCT02162836

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy